On December 10, 2024, Ambrosia Biosciences, a drug discovery company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders, announced the successful second closing of its Series A financing. This closing was led by Merck with additional participation from existing investors BVF Partners and Boulder Ventures. Wilson Sonsini Goodrich & Rosati advised Ambrosia Biosciences on the transaction.

The additional capital brings the company's total Series A financing to $25 million. Ambrosia Biosciences will use the proceeds from the round to further its drug discovery efforts and initiate pre-clinical development operations.

The Wilson Sonsini team that advised Ambrosia Biosciences on the transaction includes Brent Fassett and Alison Sechrest.

For more information, please see Ambrosia Biosciences news release.